Analysts highlighted the company as one of India’s fastest-growing CRDMOs. It noted the company’s strong portfolio of commercial molecules and sticky client relationships, which provide long-term revenue visibility. Anthem also benefits from a multi-modality platform and large-scale manufacturing capabilities, with the highest share of revenue coming from commercial products among its Indian peers.
The brokerage expects revenue to grow at a CAGR of 26% over FY23–26E, with a 15–16% increase projected for FY26E. Over FY26–28E, revenue and EBITDA are estimated to grow at CAGRs of 19% and 22%, respectively. Growth is likely to be driven by a recovery in volumes of its top product, continued momentum in legacy molecules, and incremental contributions from new molecules commercialised in FY26.
Citi also sees traction in products such as Semaglutide and Peg-Fil as a key upside trigger. Additionally, the brokerage expects margin expansion of 150–200 basis points over the medium term, supported by backward integration and operating leverage.
Anthem BioSciences is an integrated Bangalore-based Contract Research, Development, and Manufacturing Organization (CRDMO) that supports pharmaceutical and biotech companies. Founded in 2006, it provides end-to-end services—from drug discovery (small and large molecules) to preclinical evaluation, and GMP manufacturing.
The company made its stock market debut in July last year, listing at a healthy premium of 27%. The IPO witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. Anthem Biosciences had raised Rs 1,016 crore from anchor investors.
Anthem BioSciences share price has risen 15% in the last one month.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Veer Sharma
Shares of Anthem BioSciences shares will be in focus heading into trade on Tuesday after international brokerage firm Citi initiated coverage on the stock with a Buy rating and a target price of Rs 870, translating to an upside of 20.4% from current market levels.
Analysts highlighted the company as one of India’s fastest-growing CRDMOs. It noted the company’s strong portfolio of commercial molecules and sticky client relationships, which provide long-term revenue visibility. Anthem also benefits from a multi-modality platform and large-scale manufacturing capabilities, with the highest share of revenue coming from commercial products among its Indian peers.
The brokerage expects revenue to grow at a CAGR of 26% over FY23–26E, with a 15–16% increase projected for FY26E. Over FY26–28E, revenue and EBITDA are estimated to grow at CAGRs of 19% and 22%, respectively. Growth is likely to be driven by a recovery in volumes of its top product, continued momentum in legacy molecules, and incremental contributions from new molecules commercialised in FY26.
Citi also sees traction in products such as Semaglutide and Peg-Fil as a key upside trigger. Additionally, the brokerage expects margin expansion of 150–200 basis points over the medium term, supported by backward integration and operating leverage.
Anthem BioSciences is an integrated Bangalore-based Contract Research, Development, and Manufacturing Organization (CRDMO) that supports pharmaceutical and biotech companies. Founded in 2006, it provides end-to-end services—from drug discovery (small and large molecules) to preclinical evaluation, and GMP manufacturing.
The company made its stock market debut in July last year, listing at a healthy premium of 27%. The IPO witnessed robust demand, with an overall subscription of 67.42 times. The Qualified Institutional Buyers (QIB) segment was subscribed 192.80 times, Non-Institutional Investors (NII) 44.70 times, and the retail portion 5.98 times. Anthem Biosciences had raised Rs 1,016 crore from anchor investors.
Anthem BioSciences share price has risen 15% in the last one month.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)